Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright decreased their price target on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Monday, August 12th.

Oncternal Therapeutics Price Performance

NASDAQ:ONCT opened at $4.11 on Friday. The firm has a 50 day moving average of $6.13 and a 200 day moving average of $7.85. The stock has a market capitalization of $12.17 million, a price-to-earnings ratio of -0.33 and a beta of 1.36. Oncternal Therapeutics has a 52 week low of $3.25 and a 52 week high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.14. The business had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. During the same quarter last year, the company posted ($3.00) earnings per share. As a group, analysts expect that Oncternal Therapeutics will post -11.63 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.